Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Provided By GlobeNewswire
Last update: Aug 14, 2024
SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights.
Read more at globenewswire.com0.3345
-0.02 (-6.22%)
Find more stocks in the Stock Screener
TSBX Latest News and Analysis
11 days ago - ChartmillWhich stocks have an unusual volume on Wednesday?Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
